14 Feb, 2023 02:59 PM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased announce it has recei...read more
03 Aug, 2022 08:24 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the Japan Patent Office has issue...read more
29 Jul, 2022 09:40 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more
29 Jun, 2022 09:42 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agree...read more
09 Jun, 2022 10:23 AM
* Initial Placement of A$500,000 in ordinary shares at A$0.10 each (being the closing bid price yesterday, 8 June 2022) and 15,000,000 unlisted options exercisable at A$0.255 each expiring 31 March ...read more
27 Apr, 2022 11:53 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31...read more